Adaptive Biotechnologies
ADPT
271 hedge funds and large institutions have $2.18B invested in Adaptive Biotechnologies in 2025 Q3 according to their latest regulatory filings, with 55 funds opening new positions, 93 increasing their positions, 81 reducing their positions, and 25 closing their positions.
120% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 25
54% more call options, than puts
Call options by funds: $821K | Put options by funds: $534K
26% more capital invested
Capital invested by funds: $1.73B → $2.18B (+$449M)
15% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 81
12% more funds holding
Funds holding: 242 → 271 (+29)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.02% less ownership
Funds ownership: 97.52% → 95.5% (-2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$33.3M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$25.1M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$18.8M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$17.6M |
| 5 |
Jennison Associates
New York
|
+$14.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$72.9M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$38.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.8M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$10.4M |
| 5 |
JP Morgan Chase
New York
|
-$9.74M |
ADPT Hedge Fund Activity: Q3 2025 in Review
271 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q3 2025, worth a combined $2.18B — up 26% from $1.73B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new ADPT positions and 25 closed out — a net gain of 30 holders — while 93 added to existing stakes and 81 trimmed.
The largest buyer was Ameriprise, adding an estimated $33.3M. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $72.9M sold.
- 271 institutional investors held Adaptive Biotechnologies (ADPT) as of Q3 2025, up from 242 in Q2 2025.
- Funds reported $2.18B of Adaptive Biotechnologies stock for Q3 2025, up 26% quarter-over-quarter.
- 55 funds opened new Adaptive Biotechnologies positions in Q3 2025 and 25 closed out, a net change of +30 holders.
- The largest Adaptive Biotechnologies buyer in Q3 2025 was Ameriprise, an estimated $33.3M added.
- The largest Adaptive Biotechnologies seller in Q3 2025 was Rubric Capital Management (New York), an estimated $72.9M sold.
Based on aggregated 13F filings for Q3 2025.